The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition

<p>Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding...

Full description

Bibliographic Details
Main Authors: Pedro Barata, Moshe C Ornstein, Jorge A Garcia
Format: Article
Language:English
Published: Codon Publications 2017-05-01
Series:Journal of Kidney Cancer and VHL
Subjects:
Online Access:http://jkcvhl.com/index.php/jkcvhl/article/view/69